Elsevier adds half a million records from ClinicalTrials.gov to Embase, enabling a seamless search experience in the world’s most comprehensive biomedical database

Elsevier, a global leader in information and analytics, is announcing the addition of half a million records from ClinicalTrials.gov to its leading biomedical literature database, Embase. The integration will enable researchers to seamlessly view high-quality information on clinical research studies and their results alongside the peer-reviewed literature, in-press publications and conference abstracts already available in Embase. Researchers will be able to conduct more comprehensive evidence and literature searches while having the confidence they will never miss important updates relevant to their drug, therapy, or medical device.

Clinical trials data is a vital component of biomedical literature search, helping pharmaceutical and medical device companies stay informed about the latest scientific advancements, regulatory requirements, and competitive insights to support evidence-based decision-making. However, gathering data from multiple sources is currently prone to errors and is time-consuming, such as the duplication of search results, which slows research and regulatory processes. As new therapies and devices are developed and R&D organizations seek collaborative partners, they must undertake thorough searches and justifications of evidence. This process becomes challenging when data must be sourced from differing platforms, and regulatory and compliance requirements continue to evolve.

The addition of ClinicalTrials.gov data to Embase will improve researcher workflows by making clinical data searchable within Embase’s user-friendly interface. By presenting all biomedical evidence in a single platform, Embase enables researchers to better align and analyze search results, as well as export data into a citation manager. Clinical trials will be automatically indexed using the latest Emtree vocabulary, ensuring they are indexed accurately based on their title, a brief summary and detailed description. This new integration continues to support multiple use cases that Embase delivers to users, including to medical affairs, to understand clinical endpoints, outcomes and patient populations for already-approved drugs, providing competitive intelligence, supporting medical device development and approval, improving clinical trial design, and improving drug safety.

By late 2025, Embase will further expand its ClinicalTrials.gov coverage to include eligibility criteria and study plan information, reinforcing its role as a comprehensive platform for accessing both published literature and clinical trial registry data.

Mirit Eldor, Managing Director of the Life Sciences business at Elsevier, said, “Researchers are under increasing pressure to conduct comprehensive evidence searches with accuracy and efficiency, ensuring no critical information is overlooked. The incorporation of clinical trials data into Embase is the latest example of Elsevier’s commitment to developing innovative solutions that enhance researchers’ workflows. With access to comprehensive, high-quality data, researchers can reduce time spent on manual searches, while making more informed decisions that ensure the integrity of their company’s drug, therapy, or medical device. We have had many requests from customers to add Clinical Trials data into Embase and I’m delighted that we are able to improve the value that we deliver to our customers"

https://www.elsevier.com/products/embase

엘스비어 소개

엘스비어는 첨단 정보와 의사결정 지원 분야를 선도하는 글로벌 기업입니다. 100년 넘게 과학과 의료의 발전을 뒷받침하며 인류의 더 나은 미래를 위해 노력해왔습니다. 우리는 전 세계 170개국의 대학 및 기업 연구자, 의사, 간호사, 차세대 보건의료 인력과 교육자들이 중요한 업무를 수행할 수 있도록 지원하고 있습니다. 우리는 신뢰할 수 있는 근거 기반의 과학과 의학 콘텐츠에 첨단 인공지능(AI) 기술을 접목한 핵심 인사이트와 혁신적인 솔루션을 제공함으로써, 이들의 더 나은 성과 달성을 돕고자 합니다. 우리는 제품과 조직 문화 전반에 포용성과 지속 가능성의 가치를 반영하고, 함께하는 커뮤니티와의 협력을 통해 이를 실천해 나가고 있습니다. 엘스비어 재단(Elsevier Foundation)은 세계 곳곳에서 연구 및 보건 분야의 협력 사업을 후원하고 있습니다.

엘스비어는 전문가 및 비즈니스 고객을 위한 정보 기반 분석 및 의사결정 도구를 제공하는 글로벌 기업 RELX의 계열사입니다. 자세한 내용은 www.elsevier.com에서 확인하실 수 있으며, SNS @ElsevierConnect를 통해 최신 소식도 실시간으로 받아보실 수 있습니다.